Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY
Document Type and Number:
WIPO Patent Application WO/2021/149776
Kind Code:
A1
Abstract:
The present disclosure provides, for example, compounds represented by general formula (6) [in the formula, X1, X2, X3, and X4 are each independently -CR2= or -N=; R2 is, for example, a halogen atom; R1 is, for example, -S(=O)2-NH-R8; R8 is, for example, a C1-6 alkyl group; R3 is, for example, a hydrogen atom; R5 is, for example, a halogen atom; R6 is, for example, a hydrogen atom; and R4 is, for example, a cyclopropyl group] or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt. The compounds, salts, and solvates provided by the disclosure have high RAF/MEK complex stabilization activities and can be used for the treatment or prevention of cell proliferation diseases and particularly cancers.

Inventors:
ISSHIKI YOSHIAKI (JP)
WATANABE FUMIO (JP)
TOMIZAWA MASAKI (JP)
HADA KIHITO (JP)
HATTORI KAZUO (JP)
KAWASAKI KENICHI (JP)
HYODO IKUMI (JP)
AOKI TOSHIHIRO (JP)
Application Number:
PCT/JP2021/002088
Publication Date:
July 29, 2021
Filing Date:
January 21, 2021
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
CHUGAI PHARMACEUTICAL CO LTD (JP)
International Classes:
A61P35/00; A61K31/166; A61K31/18; A61K31/44; A61K31/4436; A61K31/444; A61P43/00; C07C307/10; C07C311/01; C07D213/76; C07D401/06; C07D409/12
Domestic Patent References:
WO2006011466A12006-02-02
WO2007091736A12007-08-16
Foreign References:
JP2007511614A2007-05-10
JP2016534027A2016-11-04
JP2012508203A2012-04-05
CH2676651A
Other References:
LITO, PIRO ET AL.: "Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors", CANCER CELL, vol. 25, 12 May 2014 (2014-05-12), pages 697 - 710, XP028653290, DOI: 10.1016/j.ccr.2014.03.011
NATURE, vol. 15, 2018, pages 709 - 720
MOLECULES, vol. 22, 2017, pages e1551
N. ENGL. J. MED., vol. 367, 2012, pages 1694 - 1703
JAMA, vol. 317, no. 18, 2017, pages 1844 - 1853
ANN. ONCOL., vol. 26, no. 5, 2015, pages 894 - 901
CANCER RES, vol. 73, no. 13, 2013, pages 4050 - 4060
CANCER CELL, vol. 25, no. 5, 2014, pages 697 - 710
J. CLIN. ONCOL., vol. 35, no. 15, 2017, pages 2506
NAT. REV. CLIN. ONCOL., vol. 11, 2014, pages 385 - 400
BIOORG. MED. CHEM. LETT., vol. 21, no. 6, 2011, pages 1795 - 1801
CHEM. REV., vol. 95, no. 7, 1995, pages 2457
ACC. CHEM. RES., vol. 41, pages 1461
TETRAHEDRON, vol. 48, no. 44, 1992, pages 9577
ALDRICHIMICA ACTA, vol. 38, 2005, pages 71
CHEM. SOC. REV., vol. 40, 2011, pages 5048
BIOORG. MED. CHEM. LETT., vol. 18, no. 24, 2008, pages 6501 - 6504
BIOORG. MED. CHEM. LETT., vol. 23, no. 8, 2013, pages 2384 - 2390
CHEM. MED. CHEM., vol. 10, no. 12, 2015, pages 2004 - 2013
ACS MEDCHEM. LETT., vol. 5, no. 4, 2014, pages 309 - 314
Attorney, Agent or Firm:
HASEGAWA Yoshiki et al. (JP)
Download PDF: